![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IFNAR2 |
Gene summary for IFNAR2 |
![]() |
Gene information | Species | Human | Gene symbol | IFNAR2 | Gene ID | 3455 |
Gene name | interferon alpha and beta receptor subunit 2 | |
Gene Alias | IFN-R | |
Cytomap | 21q22.11 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | P48551 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3455 | IFNAR2 | LZE2T | Human | Esophagus | ESCC | 7.21e-03 | 3.45e-01 | 0.082 |
3455 | IFNAR2 | LZE4T | Human | Esophagus | ESCC | 1.22e-04 | 1.65e-01 | 0.0811 |
3455 | IFNAR2 | LZE5T | Human | Esophagus | ESCC | 4.09e-03 | 2.34e-01 | 0.0514 |
3455 | IFNAR2 | LZE7T | Human | Esophagus | ESCC | 6.75e-03 | 2.66e-01 | 0.0667 |
3455 | IFNAR2 | LZE22T | Human | Esophagus | ESCC | 2.96e-02 | 2.90e-01 | 0.068 |
3455 | IFNAR2 | LZE24T | Human | Esophagus | ESCC | 4.36e-10 | 2.15e-01 | 0.0596 |
3455 | IFNAR2 | LZE21T | Human | Esophagus | ESCC | 1.52e-04 | 2.36e-01 | 0.0655 |
3455 | IFNAR2 | P1T-E | Human | Esophagus | ESCC | 1.46e-04 | 3.13e-01 | 0.0875 |
3455 | IFNAR2 | P2T-E | Human | Esophagus | ESCC | 4.12e-32 | 5.81e-01 | 0.1177 |
3455 | IFNAR2 | P4T-E | Human | Esophagus | ESCC | 1.62e-19 | 4.95e-01 | 0.1323 |
3455 | IFNAR2 | P5T-E | Human | Esophagus | ESCC | 5.60e-14 | 2.35e-01 | 0.1327 |
3455 | IFNAR2 | P8T-E | Human | Esophagus | ESCC | 2.63e-13 | 2.55e-01 | 0.0889 |
3455 | IFNAR2 | P9T-E | Human | Esophagus | ESCC | 5.68e-12 | 3.26e-01 | 0.1131 |
3455 | IFNAR2 | P10T-E | Human | Esophagus | ESCC | 1.44e-23 | 3.39e-01 | 0.116 |
3455 | IFNAR2 | P11T-E | Human | Esophagus | ESCC | 1.31e-15 | 5.67e-01 | 0.1426 |
3455 | IFNAR2 | P12T-E | Human | Esophagus | ESCC | 2.77e-15 | 3.00e-01 | 0.1122 |
3455 | IFNAR2 | P15T-E | Human | Esophagus | ESCC | 1.37e-08 | 2.02e-01 | 0.1149 |
3455 | IFNAR2 | P16T-E | Human | Esophagus | ESCC | 3.65e-20 | 3.65e-01 | 0.1153 |
3455 | IFNAR2 | P17T-E | Human | Esophagus | ESCC | 2.35e-07 | 2.67e-01 | 0.1278 |
3455 | IFNAR2 | P19T-E | Human | Esophagus | ESCC | 1.23e-08 | 6.06e-01 | 0.1662 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:003434013 | Esophagus | ESCC | response to type I interferon | 48/8552 | 58/18723 | 6.18e-09 | 1.26e-07 | 48 |
GO:00603375 | Esophagus | ESCC | type I interferon signaling pathway | 41/8552 | 50/18723 | 1.35e-07 | 2.17e-06 | 41 |
GO:00713575 | Esophagus | ESCC | cellular response to type I interferon | 42/8552 | 52/18723 | 2.15e-07 | 3.30e-06 | 42 |
GO:00354555 | Esophagus | ESCC | response to interferon-alpha | 17/8552 | 21/18723 | 1.03e-03 | 5.19e-03 | 17 |
GO:00096155 | Liver | Cirrhotic | response to virus | 126/4634 | 367/18723 | 2.10e-05 | 2.77e-04 | 126 |
GO:00343404 | Liver | Cirrhotic | response to type I interferon | 29/4634 | 58/18723 | 2.87e-05 | 3.64e-04 | 29 |
GO:00713572 | Liver | Cirrhotic | cellular response to type I interferon | 24/4634 | 52/18723 | 6.32e-04 | 4.83e-03 | 24 |
GO:00603372 | Liver | Cirrhotic | type I interferon signaling pathway | 23/4634 | 50/18723 | 8.62e-04 | 6.22e-03 | 23 |
GO:0035456 | Liver | Cirrhotic | response to interferon-beta | 15/4634 | 32/18723 | 5.36e-03 | 2.73e-02 | 15 |
GO:0035455 | Liver | Cirrhotic | response to interferon-alpha | 11/4634 | 21/18723 | 5.89e-03 | 2.95e-02 | 11 |
GO:0051607 | Liver | Cirrhotic | defense response to virus | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
GO:0140546 | Liver | Cirrhotic | defense response to symbiont | 84/4634 | 265/18723 | 6.02e-03 | 3.00e-02 | 84 |
GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
GO:003434011 | Liver | HCC | response to type I interferon | 43/7958 | 58/18723 | 9.93e-07 | 1.50e-05 | 43 |
GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:006033711 | Liver | HCC | type I interferon signaling pathway | 37/7958 | 50/18723 | 6.13e-06 | 7.52e-05 | 37 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516914 | Liver | Cirrhotic | Epstein-Barr virus infection | 80/2530 | 202/8465 | 1.80e-03 | 8.33e-03 | 5.13e-03 | 80 |
hsa051605 | Liver | Cirrhotic | Hepatitis C | 63/2530 | 157/8465 | 3.67e-03 | 1.49e-02 | 9.20e-03 | 63 |
hsa0516410 | Liver | Cirrhotic | Influenza A | 66/2530 | 171/8465 | 8.56e-03 | 2.91e-02 | 1.79e-02 | 66 |
hsa0516714 | Liver | Cirrhotic | Kaposi sarcoma-associated herpesvirus infection | 73/2530 | 194/8465 | 1.17e-02 | 3.81e-02 | 2.35e-02 | 73 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa051651 | Liver | Cirrhotic | Human papillomavirus infection | 124/2530 | 331/8465 | 1.55e-03 | 7.83e-03 | 4.83e-03 | 124 |
hsa0516915 | Liver | Cirrhotic | Epstein-Barr virus infection | 80/2530 | 202/8465 | 1.80e-03 | 8.33e-03 | 5.13e-03 | 80 |
hsa0516012 | Liver | Cirrhotic | Hepatitis C | 63/2530 | 157/8465 | 3.67e-03 | 1.49e-02 | 9.20e-03 | 63 |
hsa0516411 | Liver | Cirrhotic | Influenza A | 66/2530 | 171/8465 | 8.56e-03 | 2.91e-02 | 1.79e-02 | 66 |
hsa0516715 | Liver | Cirrhotic | Kaposi sarcoma-associated herpesvirus infection | 73/2530 | 194/8465 | 1.17e-02 | 3.81e-02 | 2.35e-02 | 73 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0516921 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
hsa051652 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
hsa0516021 | Liver | HCC | Hepatitis C | 94/4020 | 157/8465 | 1.11e-03 | 4.10e-03 | 2.28e-03 | 94 |
hsa0516421 | Liver | HCC | Influenza A | 101/4020 | 171/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 101 |
hsa0516721 | Liver | HCC | Kaposi sarcoma-associated herpesvirus infection | 111/4020 | 194/8465 | 3.78e-03 | 1.16e-02 | 6.45e-03 | 111 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0516931 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
hsa051653 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
hsa0516031 | Liver | HCC | Hepatitis C | 94/4020 | 157/8465 | 1.11e-03 | 4.10e-03 | 2.28e-03 | 94 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IFNAR2 | SNV | Missense_Mutation | novel | c.756N>C | p.Leu252Phe | p.L252F | P48551 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
IFNAR2 | SNV | Missense_Mutation | novel | c.1112N>A | p.Pro371His | p.P371H | P48551 | protein_coding | deleterious(0) | possibly_damaging(0.888) | TCGA-B6-A402-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PD |
IFNAR2 | SNV | Missense_Mutation | c.240N>T | p.Lys80Asn | p.K80N | P48551 | protein_coding | deleterious(0.03) | possibly_damaging(0.882) | TCGA-C5-A2LV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
IFNAR2 | SNV | Missense_Mutation | c.1225N>C | p.Glu409Gln | p.E409Q | P48551 | protein_coding | deleterious(0.04) | possibly_damaging(0.505) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
IFNAR2 | SNV | Missense_Mutation | novel | c.1173N>C | p.Leu391Phe | p.L391F | P48551 | protein_coding | tolerated(0.12) | benign(0.107) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IFNAR2 | SNV | Missense_Mutation | novel | c.1296N>C | p.Leu432Phe | p.L432F | P48551 | protein_coding | deleterious(0.04) | benign(0.326) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IFNAR2 | SNV | Missense_Mutation | c.1363N>C | p.Glu455Gln | p.E455Q | P48551 | protein_coding | deleterious(0.04) | possibly_damaging(0.656) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
IFNAR2 | SNV | Missense_Mutation | novel | c.1163N>G | p.Leu388Trp | p.L388W | P48551 | protein_coding | deleterious(0.04) | possibly_damaging(0.744) | TCGA-VS-A9UB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IFNAR2 | SNV | Missense_Mutation | novel | c.799N>G | p.Ile267Val | p.I267V | P48551 | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
IFNAR2 | SNV | Missense_Mutation | c.917N>C | p.Tyr306Ser | p.Y306S | P48551 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | agonist | CHEMBL1201560 | PEGINTERFERON ALFA-2A | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | INTERFERON BETA-1B | |||
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | INTERFERON ALFACON-1 | |||
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | Interferon Alfa-2b, Recombinant | |||
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | agonist | CHEMBL1201558 | INTERFERON ALFA-2B | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | Interferon alfa-n1 | |||
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | agonist | CHEMBL1201557 | INTERFERON ALFACON-1 | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | agonist | CHEMBL2108677 | PEGINTERFERON BETA-1A | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | agonist | CHEMBL1201563 | INTERFERON BETA-1B | |
3455 | IFNAR2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE | Anifrolumab | ANIFROLUMAB |
Page: 1 2 3 |